×
About 497 results

ALLMedicine™ Acute Bronchospasm Center

Research & Reviews  41 results

Unusual Presentation of Atrial Myxoma: A Case Report and Review of the Literature.
https://doi.org/10.12659/AJCR.931437
The American Journal of Case Reports; Jaravaza DR, Lalla U et. al.

May 3rd, 2021 - BACKGROUND Although rare, atrial myxoma is the most common benign cardiac tumor. The recognized triad of presenting symptoms relates to constitutional, embolic, and obstructive effects produced by the tumor. However, the presentation may be non-sp...

Computed Tomography Scan Evidence of Bronchospasm and Its Resolution During Computed To...
https://doi.org/10.1213/XAA.0000000000001388
A&A Practice; Munaf M, Gadhinglajkar S et. al.

Mar 8th, 2021 - Bronchospasm in children is common; however, due to its sudden nature, radiographic correlation is uncommon. We planned a computed tomography (CT) coronary angiogram for a 5-year-old child for evaluation of Kawasaki disease. The child started to d...

Theophylline Level 
https://emedicine.medscape.com/article/2090395-overview

Feb 9th, 2020 - Reference Range Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet. [1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke...

Theophylline Level 
https://emedicine.medscape.com/article/2090395-print

Feb 9th, 2020 - Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet.[1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke.[3] In the blood...

Tissue traction microscopy to quantify muscle contraction within precision-cut lung sli...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052683
American Journal of Physiology. Lung Cellular and Molecul... Ram-Mohan S, Bai Y et. al.

Nov 27th, 2019 - In asthma, acute bronchospasm is driven by contractile forces of airway smooth muscle (ASM). These forces can be imaged in the cultured ASM cell or assessed in the muscle strip and the tracheal/bronchial ring, but in each case, the ASM is studied ...

see more →

Guidelines  1 results

NUCALA (mepolizumab) For Severe Eosinophilic Asthma
https://gskpro.com/en-us/products/nucala

NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

see more →

Drugs  197 results see all →

Clinicaltrials.gov  251 results

Unusual Presentation of Atrial Myxoma: A Case Report and Review of the Literature.
https://doi.org/10.12659/AJCR.931437
The American Journal of Case Reports; Jaravaza DR, Lalla U et. al.

May 3rd, 2021 - BACKGROUND Although rare, atrial myxoma is the most common benign cardiac tumor. The recognized triad of presenting symptoms relates to constitutional, embolic, and obstructive effects produced by the tumor. However, the presentation may be non-sp...

Fluticasone propionate and salmeterol - fluticasone propionate and salmeterol powder-Hikma Pharmaceuticals USA Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9fcfc90-3677-4a9b-900e-44417d50d507

Apr 26th, 2021 - Fluticasone propionate and salmeterol inhalation powder is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for: •Twice-daily treatment of asthma in patients aged 4 years and older. (1.1...

Fluticasone propionate and salmeterol - fluticasone propionate and salmeterol powder, metered-A-S Medication Solutions
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77269609-fb89-47c7-97cc-22e0183e91ae

Apr 15th, 2021 - Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) is indicated for the treatment of asthma in patients aged 12 years and older. Fluticasone Propionate/Salmeterol MDPI should be used for patients not adequately controlled on ...

Fluticasone propionate and salmeterol diskus - fluticasone propionate and salmeterol powder-A-S Medication Solutions
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dfadeac-6599-41c5-8e25-5f78cba17f00

Apr 15th, 2021 - Fluticasone Propionate/Salmeterol DISKUS is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) indicated for: •Twice-daily treatment of asthma in patients aged 4 years and older. (1.1) •Maintenance ...

Budesonide - budesonide suspension-Sun Pharmaceutical Industries, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a39fbcfc-3ffd-44bd-b882-01f8e1844213

Apr 15th, 2021 - Budesonide is an inhaled corticosteroid indicated for: Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age (1) Limitations of Use: Not indicated for the relief of acute bronchospasm (1) Budesonide in...

see more →

News  7 results

FDA approves benralizumab autoinjector for eosinophilic asthma
https://www.mdedge.com/pulmonary-health-hub/article/209478/asthma/fda-approves-benralizumab-autoinjector-eosinophilic?channel=94
Christopher Palmer

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

FDA Approves Mepolizumab (Nucala) for Severe Asthma
https://www.staging.medscape.com/viewarticle/853957

Nov 3rd, 2015 - The US Food and Drug Administration (FDA) approved mepolizumab (Nucala, GlaxoSmithKline) for use in combination with other medications for maintenance treatment of severe asthma in patients aged 12 years or older and with an eosinophilic phenotype...

FDA Approves Mepolizumab (Nucala) for Severe Asthma
https://www.medscape.com/viewarticle/853957

Nov 3rd, 2015 - The US Food and Drug Administration (FDA) approved mepolizumab (Nucala, GlaxoSmithKline) for use in combination with other medications for maintenance treatment of severe asthma in patients aged 12 years or older and with an eosinophilic phenotype...

FDA Approves Long-Acting COPD Inhaler
https://www.medpagetoday.com/pulmonology/smokingcopd/47038

Aug 1st, 2014 - The FDA approved another once-daily bronchodilator, olodaterol (Striverdi Respimat), for maintenance treatment of chronic obstructive pulmonary disease (COPD). Approved indications for the long-acting beta-adrenergic agonist (LABA) drug included l...

May 2005
https://www.medscape.com/viewarticle/503848_7

May 3rd, 2005 - Pulmonology Agents Manufacturer: Schering Drug Approval Classification: Original New Drug Application (Approval Date: 3/30/05) Indication:  Asmanex Twisthaler (mometasone furoate) inhaler is indicated for the maintenance treatment of asthma as pro...

see more →